Ignite Creation Date:
2024-05-06 @ 3:29 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04647344
Status:
COMPLETED
Last Update Posted:
2024-04-25
First Post:
2020-11-21
Brief Title:
A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Sponsor:
Akeso
Organization:
Akeso
Study Overview
Official Title:
An Open-label Multicenter Phase IbII Study of AK104 Combined Chemotherapy as First-line Therapy to Treat Locally Advanced or Metastatic Non-small Cell Lung Carcinoma
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase IbII open-label multicenter single arm study designed to evaluate the efficacy safety tolerability pharmacokinetic PK and immunogenicity of AK104 combined with Carboplatin and Pemetrexed Paclitaxel as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None